NEOGNeogen Corporation exhibits a mixed investment profile. While its core business in food and animal safety offers a stable, albeit slow-growth, market, current financial performance and technical indicators suggest a holding rather than a strong buy or sell recommendation. The company faces profitability challenges and mixed technical signals.
Neogen operates in the essential sectors of food and animal safety, benefiting from increasing global demand for safe food and animal welfare. However, its growth may be slower compared to high-tech sectors, and it lacks strong thematic tailwinds like AI or renewable energy.
Neogen's financials present a mixed picture. While revenue has grown, profitability has been inconsistent, with recent periods showing net losses. The balance sheet appears manageable, but cash flow from operations is a concern.
Short-term technical indicators suggest a potential upward bias, with most moving averages indicating 'Buy' signals. However, RSI is in neutral territory, and broader trends over the past year have been negative.
| Factor | Score |
|---|---|
| Food Safety Demand | 75 |
| Animal Health & Welfare | 70 |
| Genomics & Diagnostics | 65 |
| Market Disruption Potential | 40 |
| Regulatory Environment | 60 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 10 |
| Growth | 70 |
| Balance Sheet Health | 70 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 50 |
| Short-term Moving Averages | 80 |
| Price Action | 40 |
| Volume Trends | 60 |
Positive Price Action
The current price is $4.955, which is up 0.71% for the day. The 5-day performance is -5.08%, 1-month performance is 0.3%, indicating recent stability after a decline.
Improving Free Cash Flow
Free cash flow has improved from -$76.16M in 2024Q2 to -$24.73M in 2023Q2, showing a positive trend in cash generation.
Negative EPS Trend
EPS has been negative for recent periods (e.g., -0.9% in 2024Q1, -2.3% in 2024Q2), indicating ongoing profitability challenges.
Negative P/E Ratio
The trailing Price-to-Earnings (P/E) ratio is -2.2, and forward P/E ratios are also negative or extremely high, signaling that the company is not currently profitable on a per-share basis.
July 2025
29
Next Earnings Date
H: $0.10
A: $0.09
L: $0.08
H: 225.00M
A: 222.53M
L: 221.00M
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared food products and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. The company was incorporated in 1981 and is headquartered in Lansing, Michigan.
7.50 USD
The 39 analysts offering 1 year price forecasts for NEOG have a max estimate of 10.00 and a min estimate of 5.00.